Skip to main content

Advertisement

Table 4 Noncompartmental pharmacokinetics in plasma following single dosing with GSK933776 a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

  Geometric mean (CV in %)
Parameters 1 mg/kg ( N/n = 6/6) 95% CI 3 mg/kg ( N/n = 6/6) 95% CI 6 mg/kg ( N/n = 6/6) 95% CI
AUC0–12 (h∙mg/ml) 0.2 (26.0) 0.1 to 0.2 1.0 (19.5) 0.9 to 1.3 1.6 (20.6) 1.3 to 2.0
AUC0–t (h∙mg/ml) 3.3 (39.3) 2.2 to 4.9 23.0 (12.8) 20.2 to 26.3 36.3 (15.3) 31.0 to 42.6
Cmax (μg/ml) 18.4 (29.0) 13.6 to 24.9 104.0 (20.0) 84.4 to 128.1 158.2 (24.0) 123.8 to 202.1
Ct (μg/ml) 0.5 (366.0) 0.1 to 2.5 1.2 (33.0) 0.9 to 1.7 1.5 (30.0) 1.1 to 2.1
tlast (h) 909.8 (105.5) 367.0 to 2,255.4 1,337.4 (0.2) 1,335.1 to 1,339.8 1,417.2 (7.0) 1,317.6 to 1,524.3
tmax (h) 11.7 (264.1) 2.6 to 53.1 2.1 (16.4) 1.8 to 2.5 1.9 (61.2) 1.1 to 3.4
  1. aAUC0–12: Area under the plasma concentration–time curve from time 0 to 12 hours postdosing; AUC0–t: Area under the plasma concentration–time curve to the last quantifiable concentration; CI: Confidence interval; Cmax: Maximum plasma concentration; Ct: Concentration at tlast; CV: Coefficient of variation; tlast: Time of last observed plasma concentration; tmax: Time of occurrence of Cmax.